- Home
- CRGX vs PERF Comparison
CRGX vs PERF Comparison
Compare CRGX & PERF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- PERF
- Stock Information
- Founded
- CRGX 2021
- PERF 2015
- Country
- CRGX United States
- PERF Taiwan
- Employees
- CRGX N/A
- PERF N/A
- Industry
- CRGX
- PERF Computer Software: Prepackaged Software
- Sector
- CRGX
- PERF Technology
- Exchange
- CRGX Nasdaq
- PERF Nasdaq
- Market Cap
- CRGX 190.0M
- PERF 191.5M
- IPO Year
- CRGX 2023
- PERF N/A
- Fundamental
- Price
- CRGX $4.27
- PERF $2.03
- Analyst Decision
- CRGX Hold
- PERF Buy
- Analyst Count
- CRGX 7
- PERF 1
- Target Price
- CRGX $4.67
- PERF $5.00
- AVG Volume (30 Days)
- CRGX 647.1K
- PERF 330.1K
- Earning Date
- CRGX 08-11-2025
- PERF 07-23-2025
- Dividend Yield
- CRGX N/A
- PERF N/A
- EPS Growth
- CRGX N/A
- PERF 43.29
- EPS
- CRGX N/A
- PERF 0.07
- Revenue
- CRGX N/A
- PERF $61,927,000.00
- Revenue This Year
- CRGX $58.18
- PERF $15.86
- Revenue Next Year
- CRGX N/A
- PERF $14.50
- P/E Ratio
- CRGX N/A
- PERF $30.38
- Revenue Growth
- CRGX N/A
- PERF 11.28
- 52 Week Low
- CRGX $3.00
- PERF $1.51
- 52 Week High
- CRGX $25.45
- PERF $3.44
- Technical
- Relative Strength Index (RSI)
- CRGX 45.02
- PERF 66.24
- Support Level
- CRGX $4.33
- PERF $1.92
- Resistance Level
- CRGX $4.48
- PERF $2.12
- Average True Range (ATR)
- CRGX 0.19
- PERF 0.12
- MACD
- CRGX -0.02
- PERF 0.03
- Stochastic Oscillator
- CRGX 21.14
- PERF 74.36
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.